{"analyses":[{"groupDescription":"t-test adjusting for lineage and ploidy","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":".15","pValueComment":"p-value from t-test after adjusted for lineage and ploidy","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.2","value":"-44"},{"groupId":"OG001","spread":"35.5","value":"-50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count\n\nMeasurement: Percentage change of leukemia cells from baseline","dispersionType":"Standard Deviation","groups":[{"description":"4 hour High-Dose Methotrexate Infusion in upfront window treatment","id":"OG000","title":"4 hr"},{"description":"24 hour High-Dose Methotrexate Infusion in upfront window treatment","id":"OG001","title":"24 hr"}],"paramType":"MEAN","populationDescription":"Three hundred twenty (320) patients were evaluable to assess the influence of infusion duration on methotrexate's antileukemic effects.","reportingStatus":"POSTED","timeFrame":"Immediately before the methotrexate infusion and three days after subsequent infusion","title":"Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)","type":"SECONDARY","unitOfMeasure":"Percent change"}